Linda OFlaherty
Overview
Explore the profile of Linda OFlaherty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
1004
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Janning M, Kobus F, Babayan A, Wikman H, Velthaus J, Bergmann S, et al.
Cancers (Basel)
. 2019 Jun;
11(6).
PMID: 31212989
Circulating tumor cells (CTCs) hold great potential to answer key questions of how non-small cell lung cancer (NSCLC) evolves and develops resistance upon anti-PD-1/PD-L1 treatment. Currently, their clinical utility in...
2.
OFlaherty L, Shnyder S, Cooper P, Cross S, Wakefield J, Pardo O, et al.
PLoS One
. 2019 Apr;
14(4):e0214610.
PMID: 30969984
Glycogen synthase kinase-3 (GSK3) is over-expressed and hyperactivated in non-small cell lung carcinoma (NSCLC) and plays a role in ensuring the correct alignment of chromosomes on the metaphase plate during...
3.
Riethdorf S, OFlaherty L, Hille C, Pantel K
Adv Drug Deliv Rev
. 2018 Jan;
125:102-121.
PMID: 29355669
The CellSearch® system (CS) enables standardized enrichment and enumeration of circulating tumor cells (CTCs) that are repeatedly assessable via non-invasive "liquid biopsy". While the association of CTCs with poor clinical...
4.
OFlaherty L, Wikman H, Pantel K
Transl Lung Cancer Res
. 2017 Sep;
6(4):431-443.
PMID: 28904887
By identifying and tracking genetic changes in primary tumors and metastases, patients can be stratified for the most efficient therapeutic regimen by screening for known biomarkers. However, retrieving tissues biopsies...
5.
Vincent E, Elder D, OFlaherty L, Pardo O, Dzien P, Phillips L, et al.
PLoS One
. 2014 Dec;
9(12):e114725.
PMID: 25486534
Background: Glycogen synthase kinase 3 (GSK3) is a central regulator of cellular metabolism, development and growth. GSK3 activity was thought to oppose tumourigenesis, yet recent studies indicate that it may...
6.
Adam J, Yang M, Bauerschmidt C, Kitagawa M, OFlaherty L, Maheswaran P, et al.
Cell Rep
. 2013 May;
3(5):1440-8.
PMID: 23643539
The identification of mutated metabolic enzymes in hereditary cancer syndromes has established a direct link between metabolic dysregulation and cancer. Mutations in the Krebs cycle enzyme, fumarate hydratase (FH), predispose...
7.
Ternette N, Yang M, Laroyia M, Kitagawa M, OFlaherty L, Wolhulter K, et al.
Cell Rep
. 2013 Mar;
3(3):689-700.
PMID: 23499446
The gene encoding the Krebs cycle enzyme fumarate hydratase (FH) is mutated in hereditary leiomyomatosis and renal cell cancer (HLRCC). Loss of FH activity causes accumulation of intracellular fumarate, which...
8.
Bardella C, Olivero M, Lorenzato A, Geuna M, Adam J, OFlaherty L, et al.
Mol Cell Biol
. 2012 May;
32(15):3081-94.
PMID: 22645311
Loss-of-function mutations of the tumor suppressor gene encoding fumarase (FH) occur in individuals with hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC). We found that loss of FH activity conferred...
9.
Adam J, Hatipoglu E, OFlaherty L, Ternette N, Sahgal N, Lockstone H, et al.
Cancer Cell
. 2011 Oct;
20(4):524-37.
PMID: 22014577
The Krebs cycle enzyme fumarate hydratase (FH) is a human tumor suppressor whose inactivation is associated with the development of leiomyomata, renal cysts, and tumors. It has been proposed that...
10.
Bardella C, El-Bahrawy M, Frizzell N, Adam J, Ternette N, Hatipoglu E, et al.
J Pathol
. 2011 Jun;
225(1):4-11.
PMID: 21630274
Germline mutations in the FH gene encoding the Krebs cycle enzyme fumarate hydratase predispose to hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome. FH-deficient cells and tissues accumulate high levels...